Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Sodium Phosphate

FDA-approved product (injectable, injection), marketed as Hydrocortone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Asthma
  • Atopic eczema
  • Bursitis
  • Cancer
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • Crohn's disease
  • Dermatitis
  • Endocrine system disease
  • Exanthem
  • Eye inflammation
  • Hemorrhoid
  • Herpes Labialis
  • and 19 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

    NCT07611786 · start 2026-10

    Registered record
    Registry ID
    NCT07611786
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    exposure to healthcare transition protocol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2029-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    Interventionexposure to healthcare transition protocol
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

    NCT07494084 · start 2026-07-16

    Registered record
    Registry ID
    NCT07494084
    Conditions
    Shift Work Schedule; Circadian Rhythm; Insulin Resistance; Circadian Misalignment
    Interventions
    Metyrapone And Hydrocortisone; Dextrose; insulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07-16
    Completion
    2029-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShift Work Schedule; Circadian Rhythm; Insulin Resistance; Circadian Misalignment
    InterventionMetyrapone And Hydrocortisone; Dextrose; insulin
    PhasePhase 4
    Registry statusRecruiting

  • V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency

    NCT06954441 · start 2025-08-15

    Registered record
    Registry ID
    NCT06954441
    Conditions
    Immunodeficiencies; Primary Immunodeficiencies (PID); Agammaglobulinemia
    Interventions
    Intravenous immunoglobulin (IVIG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-08-15
    Completion
    2027-02-27
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmunodeficiencies; Primary Immunodeficiencies (PID); Agammaglobulinemia
    InterventionIntravenous immunoglobulin (IVIG)
    PhasePhase 3
    Registry statusRecruiting

  • FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

    NCT06409364 · start 2025-08-13

    Registered record
    Registry ID
    NCT06409364
    Conditions
    Aneurysmal Subarachnoid Hemorrhage
    Interventions
    Fludrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-13
    Completion
    2030-07-31
    Enrolment
    524

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAneurysmal Subarachnoid Hemorrhage
    InterventionFludrocortisone; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery

    NCT07037043 · start 2025-04-30

    Registered record
    Registry ID
    NCT07037043
    Conditions
    Inflammation in Cardiac Surgery
    Interventions
    hydrocortisone plus fludrocortisone; placebo of hydrocortisone plus fludrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-30
    Completion
    2028-06
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation in Cardiac Surgery
    Interventionhydrocortisone plus fludrocortisone; placebo of hydrocortisone plus fludrocortisone
    PhasePhase 3
    Registry statusRecruiting

  • Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    NCT06136624 · start 2023-12-31

    Registered record
    Registry ID
    NCT06136624
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Opevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone; Fludrocortisone acetate; Prednisone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-31
    Completion
    2030-02-15
    Enrolment
    1,310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionOpevesostat; Abiraterone acetate; Enzalutamide; Hydrocortisone +3 more
    PhasePhase 3
    Registry statusRecruiting

  • Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

    NCT05299554 · start 2022-04-01

    Registered record
    Registry ID
    NCT05299554
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Chronocort
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-04-01
    Completion
    2026-01-15
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionChronocort
    PhasePhase 3
    Registry statusCompleted

  • Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment

    NCT05193396 · start 2022-02-01

    Registered record
    Registry ID
    NCT05193396
    Conditions
    Adrenal Insufficiency; Polymyalgia Rheumatica (PMR); Giant Cell Arteritis (GCA)
    Interventions
    Hydrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-02-01
    Completion
    2026-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenal Insufficiency; Polymyalgia Rheumatica (PMR); Giant Cell Arteritis (GCA)
    InterventionHydrocortisone; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    NCT04501614 · start 2021-02-24

    Registered record
    Registry ID
    NCT04501614
    Conditions
    Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL); Ph+ Mixed Phenotype Acute Leukemia (MPAL); Philadelphia Chromosome-Like ALL (Ph-like ALL)
    Interventions
    Ponatinib; Chemotherapy Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-02-24
    Completion
    2024-07-19
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL); Ph+ Mixed Phenotype Acute Leukemia (MPAL); Philadelphia Chromosome-Like ALL (Ph-like ALL)
    InterventionPonatinib; Chemotherapy Agents
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

    NCT05276323 · start 2020-10-01

    Registered record
    Registry ID
    NCT05276323
    Conditions
    Atopic Dermatitis
    Interventions
    Medihoney Derma Cream; Hydrocortisone 1% cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-01
    Completion
    2021-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionMedihoney Derma Cream; Hydrocortisone 1% cream
    PhasePhase 2
    Registry statusCompleted

  • Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)

    NCT04301479 · start 2020-03

    Registered record
    Registry ID
    NCT04301479
    Conditions
    Vasoplegia; Cardiac Surgery
    Interventions
    hydrocortisone sodium succinate; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-03
    Completion
    2021-03
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasoplegia; Cardiac Surgery
    Interventionhydrocortisone sodium succinate; Saline
    PhasePhase 3
    Registry statusUnknown

  • Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma

    NCT04016220 · start 2019-05-20

    Registered record
    Registry ID
    NCT04016220
    Conditions
    Acute Asthma
    Interventions
    Budesonide; normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2019-05-20
    Completion
    2020-05-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Asthma
    InterventionBudesonide; normal saline
    PhasePhase 1
    Registry statusUnknown

  • Analgesic Effect of Pulmonary Recruitment and Intraperitoneal Hydrocortisone in Laparoscopic Gynecological Surgery

    NCT03845608 · start 2019-03

    Registered record
    Registry ID
    NCT03845608
    Conditions
    Laparoscopic Gynecological Surgery
    Interventions
    Pulmonary Recruitment Maneuver
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-03
    Completion
    2019-11
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaparoscopic Gynecological Surgery
    InterventionPulmonary Recruitment Maneuver
    PhasePhase 4
    Registry statusUnknown

  • Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

    NCT03532022 · start 2018-10-04

    Registered record
    Registry ID
    NCT03532022
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Chronocort®; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-10-04
    Completion
    2021-07-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionChronocort®; Standard Care
    PhasePhase 3
    Registry statusWithdrawn

  • Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults

    NCT04492280 · start 2018-09-01

    Registered record
    Registry ID
    NCT04492280
    Conditions
    Septic Shock
    Interventions
    Hydrocortisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2019-09-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionHydrocortisone
    PhasePhase 4
    Registry statusCompleted